Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-08T02:41:41.471Z Has data issue: false hasContentIssue false

Chapter 6 - Tardive syndromes

Clinical manifestations, pathophysiology, and epidemiology

Published online by Cambridge University Press:  05 July 2015

By
Daniel Tarsy  and
Raminder Parihar
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 61 - 71
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Tarsy, D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983; 6: 91–99.CrossRefGoogle ScholarPubMed
Tarsy, D. Tardive dyskinesia. In: Hurtig, HI, Dashe, JF, eds. UpToDate. Wolters Kluwer 2014.Google Scholar
Tarsy, D, Baldessarini, RJ. Tardive dyskinesia. Ann Rev Med 1984; 35:605–623.CrossRefGoogle ScholarPubMed
Jankovic, J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995; 18: 197–214.CrossRefGoogle ScholarPubMed
Waln, O, Jankovic, J. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet Mov 2013; http://tremorjournal.org/article/view/161.CrossRefGoogle Scholar
Bhidayasiri, R, Boonyawairoj, S. Spectrum of tardive syndromes: Clinical recognition and management. Postgrad Med J 2011;87:132–141.CrossRefGoogle ScholarPubMed
Stacy, M, Cardoso, F, Jankovic, J. Tardive stereotypy and other movement disorders in tardive dyskinesia. Neurology 1993;43:937–941.CrossRefGoogle Scholar
Marsden, CD, Tarsy, D, Baldessarini, RJ. Spontaneous and drug-induced movement disorders in psychotic patients. In: Psychiatric Aspects of Neurologic Disease. Benson, DF, Blumer, D (Eds) Grune and Stratton, New York, 1975. p. 219–265.Google Scholar
Tarsy, D, Granacher, R, Bralower, M. Tardive dyskinesia in young adults. Am J Psychiatry 1977;134:1032–1034.Google ScholarPubMed
Burke, RE, Fahn, S, Jankovic, J et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–1346.CrossRefGoogle ScholarPubMed
Kiriakakis, V, Bhatia, KP, Quinn, NP, et al. The natural history of tardive dystonia. Brain 1998;121:2053–2066.CrossRefGoogle ScholarPubMed
Tarsy, D. Akathisia. In: Joseph, AB, Young, RR, eds. Movement Disorders in Neurology and Neuropsychiatry, Joseph, AB, Young, RR (Eds) Blackwell, Boston 1999; 75–83.Google Scholar
Stacy, M, Jankovic, J. Tardive tremor. Mov Disord 1992;7:53–57.CrossRefGoogle ScholarPubMed
Tarsy, D, Indorf, G. Tardive tremor due to metoclopramide. Mov Disord 2002;17:620–621.CrossRefGoogle ScholarPubMed
Tarsy, D. Baldessarini, RJ. The tardive dyskinesia syndrome. In: Clinical Neuropharmacology, Klawans, HL (Ed) Raven Press, New York, 1976. p. 29–61.Google Scholar
Rich, MW, Radwany, SM. Respiratory dyskinesia. An under-recognized phenomenon. Chest 1994; 105: 1826–1832.Google ScholarPubMed
Playford, ED, Britton, TC, Thompson, PD, et al. Exacerbation of postural tremor with emergence of parkinsonism after treatment with neuroleptic drugs. J Neurol Neurosurg Psychiatry 1995;58:487–489.CrossRefGoogle ScholarPubMed
Goetz, CG. Drug-induced parkinsonism and idiopathic Parkinson’s disease. Arch Neurol 1983;40:325–326.CrossRefGoogle ScholarPubMed
Chabolla, DR, Maraganore, DM, Ahlskog, JE. Drug-induced parkinsonism as a risk factor for Parkinson’s disease: A historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724–727.CrossRefGoogle ScholarPubMed
Lorberboym, M, Treves, TA, Melamed, E, et al. [123]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord 2006;21:510–514.CrossRefGoogle Scholar
Lim, TT, Ahmed, A, Itin, I, et al. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? Intern J Neuroscience 2013;123(3):170–4.CrossRefGoogle ScholarPubMed
Gardos, G, Cole, JO, Tarsy, D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978;135:1321–1324.Google ScholarPubMed
Polizos, P, Engelhardt, DM, Hoffman, SP, et al. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizo 1973;3:247–253.CrossRefGoogle ScholarPubMed
Gardos, G, Casey, DE, Cole, JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836–841.Google ScholarPubMed
Fernandez, HH, Krupp, B, Friedman, JJ. The course of tardive dyskinesia and parkinsonism in psychiatric patients: 14-year follow-up. Neurology 2001;56:805–807.CrossRefGoogle ScholarPubMed
Yassa, R, Camille, Y, Belzile, L. Tardive dyskinesia in the course of antidepressant therapy: A prevalence study and review of the literature. J Clin Psychopharm 1987;7:243–246.CrossRefGoogle ScholarPubMed
Kane, JM, Smith, JM. Tardive dyskinesia. Prevalence and risk factors, 1959–1979. Arch Gen Psychiatry 1982; 39: 473–481.CrossRefGoogle Scholar
Harrison, PJ. The neuropathological effects of antipsychotic drugs. Schizophrenia Res 1999; 40:87–99.CrossRefGoogle ScholarPubMed
Kapur, S, Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics: A new hypothesis. Am J Psychiatry 2001;158:360–369.CrossRefGoogle ScholarPubMed
Tarsy, D, Baldessarini, RJ. Pharmacologically induced behavioral sensitivity to apomorphine. Nature (New Biol) 1973;245:262–263.CrossRefGoogle Scholar
Tarsy, D, Baldessarini, RJ. Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 1974; 13: 927–940.CrossRefGoogle ScholarPubMed
Lee, T, Seeman, P, Tourtelotte WW, et al. Binding of 3H-neuroleptic and 3H-apomorphine in schizophrenic brains. Nature 1980; 274: 897–900.CrossRefGoogle Scholar
Gerlach, J, Hansen, L. Clozapine and D-1/D-2 antagonism in extrapyramidal functions. Br J of Psychiatry 1992; 160 (Suppl 17) 34–37.CrossRefGoogle Scholar
Gunne, LM, Haggstrom, JE, Sjoquist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984; 309: 347–349.CrossRefGoogle ScholarPubMed
De Keyser, J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 1991;14:562–565.CrossRefGoogle ScholarPubMed
Lohr, JB, Kuczenski, R, Niculescu, AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003;17:47–62.CrossRefGoogle ScholarPubMed
Teo, JT, Edwards, MJ, Bhatia, K. Tardive dyskinesia caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012;27:1205–15.CrossRefGoogle ScholarPubMed
Weiden, PJ, Mann, J, Hass, G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144:1148–1153.Google ScholarPubMed
Baldessarini, RJ, Cole, JO, Davis, JM, Gardos, G, Preskorn, HS, Simpson, GM, Tarsy, D. Tardive dyskinesia. American Psychiatric Association Task Force on Late Effects of Antipsychotic Drugs. American Psychiatric Association, Washington, 1980. Am J Psychiatry 1980; 137:1163–1172.Google Scholar
Kane, JM, Woerner, M, Weinhold, P, Wegner, J, Kinon, D. A prospective study of tardive dyskinesia development: Preliminary results. J Clin Psychopharmacol 1982; 2:345–349.CrossRefGoogle ScholarPubMed
Morgenstern, H, Glazer, WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 1993; 50:723–733.CrossRefGoogle ScholarPubMed
Glazer, WM, Morgenstern, H, Doucette, JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133–139.Google ScholarPubMed
Woerner, MG, Alvir, JMJ, Saltz, BL, Lieberman, JA, Kane, JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155:1521–1528.CrossRefGoogle ScholarPubMed
Jeste, DV, Carigiuri, NP, Paulsen, JS, Heaton, RK, Lacro, JP, Harris, MJ, Bailey, A, Fell, RL, McAdams, LA. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756–765.CrossRefGoogle ScholarPubMed
Tarsy, D, Baldessarini, RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Dis 2006;2:589–598.CrossRefGoogle Scholar
Smith, JM, Baldessarini, RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37:1368–1373.CrossRefGoogle ScholarPubMed
Tenback, DE, van Harten, PN, Sloof, CJ, et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163:1438–1440.CrossRefGoogle Scholar
Muller, DJ, Shinkai, T, De Luca, V, et al. Clinical implications of pharmacogenetics for tardive dyskinesia. The Pharmacogenomic Journal 2004; 4:77–87.CrossRefGoogle ScholarPubMed
Oosthuizen, PP, Emsley, R, Stephanus Maritz, J, Turner, JA, Keyter, N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64:1075–1080.CrossRefGoogle ScholarPubMed
Tarsy, D, Lungo, C, Baldessarini, RJ. In: Weiner, WJ, Tolosa, E, eds. Epidemiology of tardive dyskinesia. Handbook of Clinical Neurology, 32d edition. Amsterdam, Elsevier, 2011; 601–616.Google Scholar
Van Os, J, Fahy, T, Jones, P, Harvey, I, Toone, B, Murray, R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997; 96:206–216.CrossRefGoogle ScholarPubMed
Van Harten, PN, Hoek, HW, Matroos, GE, Koeter, M, Kahn, RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao extrapyramidal syndromes study III. Am J Psychiatry 1998; 155:565–567.CrossRefGoogle ScholarPubMed
Muscettola, G, Barbato, G, Pampallona, S, Casiello, M, Bollini, P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 1999; 19:203–208.CrossRefGoogle ScholarPubMed
Halliday, J, Farrington, S, MacDonald, S, MacEwan, , Sharkey, V, McCreadie, R. Nithsdale schizophrenia surveys 23: Movement disorders. Br J Psych 2002;181:422–427.CrossRefGoogle ScholarPubMed
Correll, CU, Leucht, S, Kane, JM. Reduced risk for tardive dyskinesia associated with second generation antipsychotics: Systematic review of one-year studies. Am J Psychiatry 2004; 161:414–425.CrossRefGoogle Scholar
Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151–156.CrossRefGoogle ScholarPubMed
Baldessarini, RJ, Tarazi, FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman, JG, Limbird, LE, Gilman, AG, eds. Goodman and Gilman’s The Pharmacologic Basis of Therapeutics, 11th ed. New York, McGraw-Hill Press, 2005;461–500.Google Scholar
Tarsy, D, Baldessarini, RJ, Tarazi, FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16:23–45.CrossRefGoogle ScholarPubMed
Caroff, SN, Mann, SC, Campbell, EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002;63 (Suppl 4):12–19.Google ScholarPubMed
Miller del, D, Eudicone, JM, Pikalov, A, et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving ariprazole or haloperidol for the treatment of schizophrenia: post hoc analysis. J Clin Psychiatry 2007;68:1901–1906.CrossRefGoogle ScholarPubMed
Tardive dyskinesia: a Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association Press. 1992.Google Scholar
Miller, LG, Jankovic, J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Int Med 1989;149:2486–2492.CrossRefGoogle ScholarPubMed
Kenney, C, Hunter, C, Davidson, A, et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008;48:379–384.CrossRefGoogle ScholarPubMed
Rao, AS, Camilleri, M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11–19.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×